Lupin and Merck Serono enter into strategic alliance
As part of this partnership, around 20 more new products will be added to the current portfolio, with first launches likely to happen in 2016. With specific focus
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna™ (ataluren) in the European Union. In August of this year, Translarna received approval